comprehensive -WSS

comprehensive

author：knowledge 2025-09-28 00:08:59 Page View：178

close-up of psoriasis on a hand. -- biotech coverage from STAT — A close-up of psoriasis on a hand. Adobe

San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.

Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.

Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Methadone treatment changes are coming. Do they go far enough?
Next article： George Santos makes 1st court appearance after pleading not guilty to 13 counts

explore

At least 13 dead in Texas as scorching temps continue

1:17FirefighterEMTWilliamDorseyandfirefighterEMTRodrigoPinedatreatamigrantwomansufferingfromheatexha

'Essentially witchcraft:' A former naturopath takes on the field

ErosDervishiforSTATBrittHermesonceconsideredherselfadoctor.Now,she’sanapostate.Hermesspentthreeyears

In age of alternative facts, a scholarly course on calling out crap

Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

ALS patient reclaims some autonomy thanks to wearable 'robot'

AlexHogan/STATJohnGoodsonpracticedmedicineforalmost50yearsatMassachusettsGeneralHospitalinBoston.Asa